Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: wpckr who wrote (719)	9/1/1998 10:12:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 1686

Due diligence is tough to do on any company. Biotech and pharmaceutical companies are tough because their development programs resemble evolutionary trees with lots of dead ends and product off-shoots from primary branches. Biogen's recent price drop is a real buying opportunity. Earnings are still growing at a rapid rate, and VLA4, 5C8, LFA3TIP and CVT124 are steadily moving through their respective clinical trials. Each of these product can be at least as big as Avonex and all have the possibility of eclipsing Avonex in terms of revenue - especially 5C8 and VLA4. Biogen has $600MM in the bank as well, and are adding to that sum every quarter. The company has superb management - no half-assed decisions are made for the sake of the decision itself. Practical considerations rule the decision-making process. Biogen set out to make itself a full-blown pharmaceutical operating company and they have done it. Now they are building towards becoming one of the big players. It is happening. Results should appear soon for some clinical trials. Biogen is moving ahead strongly with their programs. From what I know, when the company commits resources this way, there is an excellent chance of success.